The cell and gene therapy sector’s focus on outsourcing is a major area of on-going concern due to the shortage of suitable manufacturing facilities and qualified outsourcing staff. As biopharma companies take advantage of the extended expertise of outsourcing, others have opted to build their own manufacturing facilities or perform at least a portion of the manufacturing process in house. Indeed, the cell therapy, gene therapy, and gene-modified cell therapy spaces have and will continue to evolve rapidly, as will their manufacturing processes. This collection of articles weighs the economic benefits of outsourcing (i.e. productivity, efficiency, time-to-market, and quality gains) as well as best practices for selecting an outsourcing partner. Here you’ll find information about the current limitations associated with a complicated manufacturing process as well as existing and promising opportunities and developments needed to outsource most — if not all components — of the value chain.